Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 2:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 55 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Meningococcal group B vaccine Clear all
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study of the Safety of Menactra® Vaccine When Administered With Other Pediatric Vaccines to Healthy Toddlers

NCT00483574
View directory record Official record
Conditions
Meningococcal Meningitis, Measles, Mumps, Rubella, Varicella
Interventions
Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate, Measles-mumps-rubella-varicella vaccine, Routine paediatric vaccine - Pneumococcal conjugate (PCV), Routine paediatric vaccine - Hepatitis A
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
9 Months to 12 Months
Enrollment
1,378 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
78
States / cities
Birmingham, Alabama • Dothan, Alabama • Pinson, Alabama + 68 more
Source: ClinicalTrials.gov public record
Updated May 16, 2016 · Synced Oct 7, 2026, 2:37 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Clinical Trial to Study the Safety, Tolerance and Immunogenic Response to Gardasil and Bivalent rLP2086 Vaccine When Given at the Same Time to Children Between the Ages of 11 and 17

NCT01461993
View directory record Official record
Conditions
Vaccines, Meningococcal Vaccines
Interventions
rLP2086 and Gardasil, rLP2086, Gardasil
Biological
Lead sponsor
Pfizer
Industry
Eligibility
11 Years to 17 Years
Enrollment
2,499 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
87
States / cities
Daphne, Alabama • Chandler, Arizona • Jonesboro, Arkansas + 57 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2018 · Synced Oct 7, 2026, 2:37 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Trial to Describe the Immunogenicity and Safety of 2 Doses of Bivalent rLP2086 (Trumenba) and a Pentavalent Meningococcal Vaccine in Healthy Subjects >=10 to <26 Years of Age.

NCT03135834
View directory record Official record
Conditions
Meningococcal Vaccine
Interventions
MenABCWY, Saline, rLP2086, MenACWY-CRM
Biological
Lead sponsor
Pfizer
Industry
Eligibility
10 Years to 25 Years
Enrollment
1,610 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
60
States / cities
Birmingham, Alabama • Huntsville, Alabama • Fountain Hills, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2023 · Synced Oct 7, 2026, 2:37 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study to Assess the Safety and Immunogenicity of GSK Meningococcal Group B Vaccine When Administered Concomitantly With GSK Meningococcal MenACWY Conjugate Vaccine in Healthy Subjects of 16-18 Years of Age

NCT04318548
View directory record Official record
Conditions
Infections, Meningococcal
Interventions
Meningococcal Group B Vaccine (GSK3536829A) (rMenB+OMV NZ), Meningococcal MenACWY Conjugate Vaccine (GSK3536820A) (MenA lyo + MenCWY liquid), Placebo
Combination Product · Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
16 Years to 18 Years
Enrollment
945 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
49
States / cities
Phoenix, Arizona • Bell Gardens, California • Los Angeles, California + 35 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2025 · Synced Oct 7, 2026, 2:37 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

MenB-FHbp or MenACWY-TT/MenB-FHbp Vaccine in MenB-4C Primed Young Adults

NCT07197762
View directory record Official record
Conditions
Neisseria Meningitidis
Interventions
Trumenba, PENBRAYA
Biological
Lead sponsor
Emory University
Other
Eligibility
18 Years to 25 Years
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Oct 7, 2026, 2:37 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

The Long-term Antibody Persistence of GSK Biologicals' Meningococcal Vaccine GSK134612 in Healthy Toddlers

NCT00718666
View directory record Official record
Conditions
Infections, Meningococcal
Interventions
Meningococcal vaccine GSK134612
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
2 Years to 6 Years
Enrollment
387 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2014
U.S. locations
14
States / cities
Benton, Arkansas • Little Rock, Arkansas • Antioch, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2019 · Synced Oct 7, 2026, 2:37 PM EDT
Completed No phase listed Observational Results available

A Study to Learn About How Trumenba Vaccine Shots Work Against Gonorrhea Infection in Teenagers and Young Adults in the United States.

NCT05873751
View directory record Official record
Conditions
Gonorrhea, Chlamydia, Meningococcal Vaccines
Interventions
Trumenba Vaccine, MenACWY Vaccine
Biological
Lead sponsor
Pfizer
Industry
Eligibility
15 Years to 30 Years
Enrollment
1,307,378 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 17, 2025 · Synced Oct 7, 2026, 2:37 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

MenB Vaccine: Implementation Via Information, Empowerment and Accessibility

NCT02975596
View directory record Official record
Conditions
Meningococcal Vaccine
Interventions
Awareness, Education, Empowerment, Accessibility
Other
Lead sponsor
University of Florida
Other
Eligibility
16 Years to 99 Years
Enrollment
1,326 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
6
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 6, 2020 · Synced Oct 7, 2026, 2:37 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Study on the Safety, Effectiveness and Immune Response of Meningococcal Combined ABCWY Vaccine in Healthy Adolescents and Adults

NCT04886154
View directory record Official record
Conditions
Infections, Meningococcal
Interventions
MenABCWY-2Gen low dose vaccine, MenABCWY-2Gen high dose vaccine, Placebo, MenB vaccine, MenACWY vaccine
Combination Product · Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
10 Years to 50 Years
Enrollment
1,440 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
12
States / cities
Colorado Springs, Colorado • Longmont, Colorado • Doral, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated May 31, 2025 · Synced Oct 7, 2026, 2:37 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy Toddlers

NCT00422292
View directory record Official record
Conditions
Meningococcal Meningitis, Measles, Mumps, Rubella, Varicella
Interventions
Meningococcal Polysaccharide Diphtheria Conjugate Vaccine, Measles, Mumps, Rubella and Varicella
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
9 Months to 12 Months
Enrollment
1,664 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
87
States / cities
Tuscaloosa, Alabama • Tucson, Arizona • Jonesboro, Arkansas + 74 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2016 · Synced Oct 7, 2026, 2:37 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 12 to 15 Months of Age.

NCT00345683
View directory record Official record
Conditions
Haemophilus Influenzae Type b, Neisseria Meningitidis
Interventions
GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine combined (792014), PedvaxHIB, Prevnar, M-M-R II, Varivax
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Months to 15 Months
Enrollment
4,021 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
55
States / cities
Birmingham, Alabama • Benton, Arkansas • Jonesboro, Arkansas + 45 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2016 · Synced Oct 7, 2026, 2:37 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Study of a Novel Multicomponent Meningococcal Group B Vaccine When Given Alone or With Other Licensed Vaccines in Adults, Adolescents, Toddlers and Infants

NCT04825223
View directory record Official record
Conditions
Meningococcal Immunisation, Healthy Volunteers
Interventions
Multicomponent Meningococcal B Vaccine, Meningococcal Group B Vaccine MenB, Meningococcal Group B Vaccine (recombinant deoxyribonucleic acid [rDNA], component, adsorbed), Placebo, Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine MenACYW conjugate vaccine
Drug
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
42 Days to 50 Years
Enrollment
576 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
8
States / cities
Guntersville, Alabama • San Diego, California • Tampa, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2025 · Synced Oct 7, 2026, 2:37 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety Study of GSK's MenABCWY Vaccine in Healthy Adolescents and Adults Previously Primed With MenACWY Vaccine

NCT04707391
View directory record Official record
Conditions
Meningitis, Meningococcal
Interventions
MenABCWY vaccine, Placebo, MenACWY vaccine, MenB vaccine
Combination Product · Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
15 Years to 25 Years
Enrollment
1,250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
48
States / cities
Jonesboro, Arkansas • Banning, California • Chula Vista, California + 42 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2024 · Synced Oct 7, 2026, 2:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Phase 1 Safety and Immunogenicity of Meningococcal Vaccine

NCT00678652
View directory record Official record
Conditions
Meningococcal Infection, Group B
Interventions
10 μg Group B Meningococcal 8570 HOPS-G NOMV Vaccine, 25 μg Group B Meningococcal 8570 HOPS-G NOMV Vaccine, 50 μg Group B Meningococcal 8570 HOPS-G NOMV Vaccine, 75 μg Group B Meningococcal 8570 HOPS-G NOMV Vaccine
Biological
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 45 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 18, 2017 · Synced Oct 7, 2026, 2:37 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Study of an Investigational Pentavalent Meningococcal ABCYW Vaccine in Adults and Adolescents

NCT06128733
View directory record Official record
Conditions
Meningococcal Immunisation, Healthy Volunteers
Interventions
Pentavalent Meningococcal ABCYW vaccine, MenACYW conjugate vaccine, Meningococcal group B vaccine, Placebo, MenABCYW conjugate vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
10 Years to 25 Years
Enrollment
1,215 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
46
States / cities
Birmingham, Alabama • Guntersville, Alabama • Tempe, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Oct 7, 2026, 2:37 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes

NCT06033261
View directory record Official record
Conditions
Genital Herpes
Interventions
mRNA-1608, BEXSERO
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
303 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
23
States / cities
Birmingham, Alabama • Tucson, Arizona • Beverly Hills, California + 20 more
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 7, 2026, 2:37 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Infants

NCT00474526
View directory record Official record
Conditions
Meningitis, Meningococcal
Interventions
Meningococcal ACWY Conjugate Vaccine, DTaP-IPV-HBV, Hib, Rotavirus, Pneumococcal 7-valent Conjugate Vaccine, HAV, MMR-V, DTaP
Biological
Lead sponsor
Novartis Vaccines
Industry
Eligibility
2 Months to 2 Months
Enrollment
4,545 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
53
States / cities
Bessemer, Alabama • Birmingham, Alabama • Downey, California + 43 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2014 · Synced Oct 7, 2026, 2:37 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Study of the Safety and Immune Response of Two Serogroup B Meningococcal Vaccines Administered to Healthy Adolescents

NCT00297817
View directory record Official record
Conditions
Meningococcal Disease
Interventions
serogroup B meningococcal vaccine
Biological
Lead sponsor
Novartis Vaccines
Industry
Eligibility
11 Years to 18 Years
Enrollment
203 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
8
States / cities
Encinitas, California • Atlanta, Georgia • St Louis, Missouri + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2016 · Synced Oct 7, 2026, 2:37 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study of Menactra® in Children Aged 4 to 6 Years When Administered Concomitantly With a Fifth Dose of DAPTACEL®

NCT00355121
View directory record Official record
Conditions
Meningococcal Meningitis, Tetanus, Diphtheria, Pertussis, Poliomyelitis
Interventions
Polysaccharide Diphtheria Toxoid Conjugate Vaccine
Biological
Lead sponsor
Sanofi
Industry
Eligibility
4 Years to 7 Years
Enrollment
882 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
26
States / cities
Little Rock, Arkansas • Boulder, Colorado • Atlanta, Georgia + 23 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2011 · Synced Oct 7, 2026, 2:37 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Mucosal Immunity Against Neisseria Gonorrhoeae After 4CMenB Vaccination

NCT04722003
View directory record Official record
Conditions
Gonorrhoea
Interventions
Meningococcal Group B Vaccine, Placebo
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 5, 2024 · Synced Oct 7, 2026, 2:37 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Safety of Novartis MenACWY Conjugate Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants

NCT00806195
View directory record Official record
Conditions
Meningitis, Meningococcal Infection
Interventions
MenACWY-CRM197, DTaP (Diptheria, Tetanus, Pertussis) Vaccine, Hib (Haemophilus influenza b) Vaccine, IPV (Inactivated Polio Vaccine) Vaccine, Pneumococcal conjugate Vaccine, MMR (Measles, Mumps, and Rubella) Vaccine, Varicella Vaccine, Hepatitis A Virus
Biological
Lead sponsor
Novartis
Industry
Eligibility
55 Days to 89 Days
Enrollment
7,744 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
130
States / cities
Birmingham, Alabama • Dothan, Alabama • Tuscon, Arizona + 107 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2013 · Synced Oct 7, 2026, 2:37 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Trial to Assess Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Meningococcal ABCWY Vaccine as Compared to Meningococcal B Vaccine in Adolescents

NCT02212457
View directory record Official record
Conditions
Infections, Meningococcal
Interventions
Bexsero, Saline Placebo, Havrix, MenABCWY
Biological · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
10 Years to 18 Years
Enrollment
1,063 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
13
States / cities
Jonesboro, Arkansas • Hialeah, Florida • Melbourne, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2019 · Synced Oct 7, 2026, 2:37 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Immune Response After a Booster Dose of a Quadrivalent Meningococcal (MenACYW) Conjugate Vaccine When Administered Alone or Concomitantly With a Licensed Meningococcal Serogroup B Vaccine, in Participants Who Received Primary Quadrivalent Meningococcal Conjugate Vaccine (MCV4)

NCT04084769
View directory record Official record
Conditions
Meningococcal Immunisation (Healthy Volunteers)
Interventions
Meningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid Conjugate vaccine MenACYW Conjugate vaccine, Meningococcal Group B vaccine (Trumenba®), Meningococcal group B vaccine (Bexsero®)
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
13 Years to 26 Years
Enrollment
570 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
29
States / cities
Birmingham, Alabama • San Diego, California • Bardstown, Kentucky + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Oct 7, 2026, 2:37 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Detoxified J5 Core Glycolipid/ Group B Meningococcal Outer Membrane Protein Vaccine for Gram-negative Bacterial Sepsis Administered With and Without Synthetic CPG Oligodeoxynucleotide 7909 Adjuvant

NCT01164514
View directory record Official record
Conditions
Bacterial Sepsis
Interventions
CPG 7909, J5-OMP Vaccine, Placebo
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 31, 2014 · Synced Oct 7, 2026, 2:37 PM EDT